Search details
1.
Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept.
BMC Cardiovasc Disord
; 21(1): 201, 2021 04 21.
Article
in English
| MEDLINE | ID: mdl-33882846
2.
RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1ß trap, in patients with recurrent pericarditis.
Am Heart J
; 228: 81-90, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32866928
3.
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate.
Ann Rheum Dis
; 76(5): 831-839, 2017 May.
Article
in English
| MEDLINE | ID: mdl-28087506
4.
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial.
Ann Rheum Dis
; 73(6): 1107-13, 2014 Jun.
Article
in English
| MEDLINE | ID: mdl-23644549
5.
Clinical efficacy, radiographic and safety findings through 5â years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).
Ann Rheum Dis
; 73(9): 1689-94, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-24748630
6.
Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab.
Ann Rheum Dis
; 72(1): 83-8, 2013 Jan.
Article
in English
| MEDLINE | ID: mdl-22975755
7.
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.
Ann Rheum Dis
; 72(11): 1777-85, 2013 Nov.
Article
in English
| MEDLINE | ID: mdl-23161902
8.
Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
Arthritis Rheum
; 64(7): 2068-77, 2012 Jul.
Article
in English
| MEDLINE | ID: mdl-22238071
9.
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.
Arthritis Rheum
; 64(8): 2504-17, 2012 Aug.
Article
in English
| MEDLINE | ID: mdl-22378566
10.
The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy.
Arthritis Rheum
; 63(5): 1200-10, 2011 May.
Article
in English
| MEDLINE | ID: mdl-21305524
11.
Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial.
Heart
; 2020 Nov 23.
Article
in English
| MEDLINE | ID: mdl-33229362
12.
Clinical Presentation and Outcomes of Acute Pericarditis in a Large Urban Hospital in the United States of America.
Chest
; 158(6): 2556-2567, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32717264
13.
Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.
J Clin Pharmacol
; 49(9): 1056-70, 2009 Sep.
Article
in English
| MEDLINE | ID: mdl-19617465
14.
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study.
Arthritis Care Res (Hoboken)
; 68(2): 267-74, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-25779603
15.
Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials.
Arthritis Care Res (Hoboken)
; 65(2): 309-13, 2013 Feb.
Article
in English
| MEDLINE | ID: mdl-22782640
16.
Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.
Arthritis Care Res (Hoboken)
; 65(10): 1666-73, 2013 Oct.
Article
in English
| MEDLINE | ID: mdl-23666608
17.
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
Arthritis Rheum
; 60(4): 976-86, 2009 Apr.
Article
in English
| MEDLINE | ID: mdl-19333944
18.
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
Arthritis Rheum
; 58(11): 3402-12, 2008 Nov.
Article
in English
| MEDLINE | ID: mdl-18975305
19.
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).
J Rheumatol
; 35(5): 869-76, 2008 May.
Article
in English
| MEDLINE | ID: mdl-18381786
20.
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
Arthritis Rheum
; 56(9): 3096-106, 2007 Sep.
Article
in English
| MEDLINE | ID: mdl-17763439